 | • レポートコード：MRC2-11QY12447 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は虚血性脳卒中治療薬のグローバル市場について調査・分析したレポートです。種類別（組織プラスミノーゲン活性化因子、抗凝固剤、抗血小板剤、降圧剤、その他）市場規模、用途別（病院、クリニック、外来手術センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別虚血性脳卒中治療薬の競争状況、市場シェア ・世界の虚血性脳卒中治療薬市場：種類別市場規模 2015年-2020年（組織プラスミノーゲン活性化因子、抗凝固剤、抗血小板剤、降圧剤、その他） ・世界の虚血性脳卒中治療薬市場：種類別市場規模予測 2021年-2026年（組織プラスミノーゲン活性化因子、抗凝固剤、抗血小板剤、降圧剤、その他） ・世界の虚血性脳卒中治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック、外来手術センター、その他） ・世界の虚血性脳卒中治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック、外来手術センター、その他） ・北米の虚血性脳卒中治療薬市場分析：米国、カナダ ・ヨーロッパの虚血性脳卒中治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの虚血性脳卒中治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の虚血性脳卒中治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの虚血性脳卒中治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer、Merck、Boehringer Ingelheim、Sanofi、Johnson & Johnson、Bayer、Biogen、Abbott Laboratories、Genentech、Daiichi Sankyo ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Ischemic strokes occur as a result of an obstruction within a blood vessel supplying blood to the brain. The underlying condition of this type of obstruction is the development of fat deposits lining the vessel walls, which is known as atherosclerosis.
Asia Pacific is anticipated to unfold as the most promising market for the global ischemic stroke owing to increasing prevalence of stroke cases in this region. China and India are considered as a big market for ischemic stroke within the forecast period. Manufacturers are expanding their operations in Asia Pacific region as these regions hold immense potential for the market growth.
Market Analysis and Insights: Global Ischemic Stroke Drugs Market
The global Ischemic Stroke Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Ischemic Stroke Drugs Scope and Market Size
Ischemic Stroke Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Ischemic Stroke Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Pfizer
Merck
Boehringer Ingelheim
Sanofi
Johnson & Johnson
Bayer
Biogen
Abbott Laboratories
Genentech
Daiichi Sankyo
Market segment by Type, the product can be split into
Tissue Plasminogen Activator
Anticoagulant
Antiplatelet
Antihypertensive
Others
Market segment by Application, split into
Hospitals
Clinics
Ambulatory Surgical Centers
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Ischemic Stroke Drugs Revenue
1.4 Market by Type
1.4.1 Global Ischemic Stroke Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Tissue Plasminogen Activator
1.4.3 Anticoagulant
1.4.4 Antiplatelet
1.4.5 Antihypertensive
1.4.6 Others
1.5 Market by Application
1.5.1 Global Ischemic Stroke Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Ischemic Stroke Drugs Market Perspective (2015-2026)
2.2 Global Ischemic Stroke Drugs Growth Trends by Regions
2.2.1 Ischemic Stroke Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Ischemic Stroke Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Ischemic Stroke Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Ischemic Stroke Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Ischemic Stroke Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Ischemic Stroke Drugs Players by Market Size
3.1.1 Global Top Ischemic Stroke Drugs Players by Revenue (2015-2020)
3.1.2 Global Ischemic Stroke Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Ischemic Stroke Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Ischemic Stroke Drugs Market Concentration Ratio
3.2.1 Global Ischemic Stroke Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Ischemic Stroke Drugs Revenue in 2019
3.3 Ischemic Stroke Drugs Key Players Head office and Area Served
3.4 Key Players Ischemic Stroke Drugs Product Solution and Service
3.5 Date of Enter into Ischemic Stroke Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Ischemic Stroke Drugs Historic Market Size by Type (2015-2020)
4.2 Global Ischemic Stroke Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Ischemic Stroke Drugs Market Size by Application (2015-2020)
5.2 Global Ischemic Stroke Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Ischemic Stroke Drugs Market Size (2015-2020)
6.2 Ischemic Stroke Drugs Key Players in North America (2019-2020)
6.3 North America Ischemic Stroke Drugs Market Size by Type (2015-2020)
6.4 North America Ischemic Stroke Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Ischemic Stroke Drugs Market Size (2015-2020)
7.2 Ischemic Stroke Drugs Key Players in Europe (2019-2020)
7.3 Europe Ischemic Stroke Drugs Market Size by Type (2015-2020)
7.4 Europe Ischemic Stroke Drugs Market Size by Application (2015-2020)
8 China
8.1 China Ischemic Stroke Drugs Market Size (2015-2020)
8.2 Ischemic Stroke Drugs Key Players in China (2019-2020)
8.3 China Ischemic Stroke Drugs Market Size by Type (2015-2020)
8.4 China Ischemic Stroke Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Ischemic Stroke Drugs Market Size (2015-2020)
9.2 Ischemic Stroke Drugs Key Players in Japan (2019-2020)
9.3 Japan Ischemic Stroke Drugs Market Size by Type (2015-2020)
9.4 Japan Ischemic Stroke Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Ischemic Stroke Drugs Market Size (2015-2020)
10.2 Ischemic Stroke Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Ischemic Stroke Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Ischemic Stroke Drugs Market Size by Application (2015-2020)
11 India
11.1 India Ischemic Stroke Drugs Market Size (2015-2020)
11.2 Ischemic Stroke Drugs Key Players in India (2019-2020)
11.3 India Ischemic Stroke Drugs Market Size by Type (2015-2020)
11.4 India Ischemic Stroke Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Ischemic Stroke Drugs Market Size (2015-2020)
12.2 Ischemic Stroke Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Ischemic Stroke Drugs Market Size by Type (2015-2020)
12.4 Central & South America Ischemic Stroke Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Ischemic Stroke Drugs Introduction
13.1.4 Pfizer Revenue in Ischemic Stroke Drugs Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Merck
13.2.1 Merck Company Details
13.2.2 Merck Business Overview
13.2.3 Merck Ischemic Stroke Drugs Introduction
13.2.4 Merck Revenue in Ischemic Stroke Drugs Business (2015-2020)
13.2.5 Merck Recent Development
13.3 Boehringer Ingelheim
13.3.1 Boehringer Ingelheim Company Details
13.3.2 Boehringer Ingelheim Business Overview
13.3.3 Boehringer Ingelheim Ischemic Stroke Drugs Introduction
13.3.4 Boehringer Ingelheim Revenue in Ischemic Stroke Drugs Business (2015-2020)
13.3.5 Boehringer Ingelheim Recent Development
13.4 Sanofi
13.4.1 Sanofi Company Details
13.4.2 Sanofi Business Overview
13.4.3 Sanofi Ischemic Stroke Drugs Introduction
13.4.4 Sanofi Revenue in Ischemic Stroke Drugs Business (2015-2020)
13.4.5 Sanofi Recent Development
13.5 Johnson & Johnson
13.5.1 Johnson & Johnson Company Details
13.5.2 Johnson & Johnson Business Overview
13.5.3 Johnson & Johnson Ischemic Stroke Drugs Introduction
13.5.4 Johnson & Johnson Revenue in Ischemic Stroke Drugs Business (2015-2020)
13.5.5 Johnson & Johnson Recent Development
13.6 Bayer
13.6.1 Bayer Company Details
13.6.2 Bayer Business Overview
13.6.3 Bayer Ischemic Stroke Drugs Introduction
13.6.4 Bayer Revenue in Ischemic Stroke Drugs Business (2015-2020)
13.6.5 Bayer Recent Development
13.7 Biogen
13.7.1 Biogen Company Details
13.7.2 Biogen Business Overview
13.7.3 Biogen Ischemic Stroke Drugs Introduction
13.7.4 Biogen Revenue in Ischemic Stroke Drugs Business (2015-2020)
13.7.5 Biogen Recent Development
13.8 Abbott Laboratories
13.8.1 Abbott Laboratories Company Details
13.8.2 Abbott Laboratories Business Overview
13.8.3 Abbott Laboratories Ischemic Stroke Drugs Introduction
13.8.4 Abbott Laboratories Revenue in Ischemic Stroke Drugs Business (2015-2020)
13.8.5 Abbott Laboratories Recent Development
13.9 Genentech
13.9.1 Genentech Company Details
13.9.2 Genentech Business Overview
13.9.3 Genentech Ischemic Stroke Drugs Introduction
13.9.4 Genentech Revenue in Ischemic Stroke Drugs Business (2015-2020)
13.9.5 Genentech Recent Development
13.10 Daiichi Sankyo
13.10.1 Daiichi Sankyo Company Details
13.10.2 Daiichi Sankyo Business Overview
13.10.3 Daiichi Sankyo Ischemic Stroke Drugs Introduction
13.10.4 Daiichi Sankyo Revenue in Ischemic Stroke Drugs Business (2015-2020)
13.10.5 Daiichi Sankyo Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Ischemic Stroke Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Ischemic Stroke Drugs Revenue
Table 3. Ranking of Global Top Ischemic Stroke Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Ischemic Stroke Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Tissue Plasminogen Activator
Table 6. Key Players of Anticoagulant
Table 7. Key Players of Antiplatelet
Table 8. Key Players of Antihypertensive
Table 9. Key Players of Others
Table 10. Global Ischemic Stroke Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Ischemic Stroke Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Ischemic Stroke Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Ischemic Stroke Drugs Market Share by Regions (2015-2020)
Table 14. Global Ischemic Stroke Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Ischemic Stroke Drugs Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Ischemic Stroke Drugs Market Growth Strategy
Table 20. Main Points Interviewed from Key Ischemic Stroke Drugs Players
Table 21. Global Ischemic Stroke Drugs Revenue by Players (2015-2020) (Million US$)
Table 22. Global Ischemic Stroke Drugs Market Share by Players (2015-2020)
Table 23. Global Top Ischemic Stroke Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ischemic Stroke Drugs as of 2019)
Table 24. Global Ischemic Stroke Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Ischemic Stroke Drugs Product Solution and Service
Table 27. Date of Enter into Ischemic Stroke Drugs Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Ischemic Stroke Drugs Market Size by Type (2015-2020) (Million US$)
Table 30. Global Ischemic Stroke Drugs Market Size Share by Type (2015-2020)
Table 31. Global Ischemic Stroke Drugs Revenue Market Share by Type (2021-2026)
Table 32. Global Ischemic Stroke Drugs Market Size Share by Application (2015-2020)
Table 33. Global Ischemic Stroke Drugs Market Size by Application (2015-2020) (Million US$)
Table 34. Global Ischemic Stroke Drugs Market Size Share by Application (2021-2026)
Table 35. North America Key Players Ischemic Stroke Drugs Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Ischemic Stroke Drugs Market Share (2019-2020)
Table 37. North America Ischemic Stroke Drugs Market Size by Type (2015-2020) (Million US$)
Table 38. North America Ischemic Stroke Drugs Market Share by Type (2015-2020)
Table 39. North America Ischemic Stroke Drugs Market Size by Application (2015-2020) (Million US$)
Table 40. North America Ischemic Stroke Drugs Market Share by Application (2015-2020)
Table 41. Europe Key Players Ischemic Stroke Drugs Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Ischemic Stroke Drugs Market Share (2019-2020)
Table 43. Europe Ischemic Stroke Drugs Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Ischemic Stroke Drugs Market Share by Type (2015-2020)
Table 45. Europe Ischemic Stroke Drugs Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Ischemic Stroke Drugs Market Share by Application (2015-2020)
Table 47. China Key Players Ischemic Stroke Drugs Revenue (2019-2020) (Million US$)
Table 48. China Key Players Ischemic Stroke Drugs Market Share (2019-2020)
Table 49. China Ischemic Stroke Drugs Market Size by Type (2015-2020) (Million US$)
Table 50. China Ischemic Stroke Drugs Market Share by Type (2015-2020)
Table 51. China Ischemic Stroke Drugs Market Size by Application (2015-2020) (Million US$)
Table 52. China Ischemic Stroke Drugs Market Share by Application (2015-2020)
Table 53. Japan Key Players Ischemic Stroke Drugs Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Ischemic Stroke Drugs Market Share (2019-2020)
Table 55. Japan Ischemic Stroke Drugs Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Ischemic Stroke Drugs Market Share by Type (2015-2020)
Table 57. Japan Ischemic Stroke Drugs Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Ischemic Stroke Drugs Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Ischemic Stroke Drugs Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Ischemic Stroke Drugs Market Share (2019-2020)
Table 61. Southeast Asia Ischemic Stroke Drugs Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Ischemic Stroke Drugs Market Share by Type (2015-2020)
Table 63. Southeast Asia Ischemic Stroke Drugs Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Ischemic Stroke Drugs Market Share by Application (2015-2020)
Table 65. India Key Players Ischemic Stroke Drugs Revenue (2019-2020) (Million US$)
Table 66. India Key Players Ischemic Stroke Drugs Market Share (2019-2020)
Table 67. India Ischemic Stroke Drugs Market Size by Type (2015-2020) (Million US$)
Table 68. India Ischemic Stroke Drugs Market Share by Type (2015-2020)
Table 69. India Ischemic Stroke Drugs Market Size by Application (2015-2020) (Million US$)
Table 70. India Ischemic Stroke Drugs Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Ischemic Stroke Drugs Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Ischemic Stroke Drugs Market Share (2019-2020)
Table 73. Central & South America Ischemic Stroke Drugs Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Ischemic Stroke Drugs Market Share by Type (2015-2020)
Table 75. Central & South America Ischemic Stroke Drugs Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Ischemic Stroke Drugs Market Share by Application (2015-2020)
Table 77. Pfizer Company Details
Table 78. Pfizer Business Overview
Table 79. Pfizer Product
Table 80. Pfizer Revenue in Ischemic Stroke Drugs Business (2015-2020) (Million US$)
Table 81. Pfizer Recent Development
Table 82. Merck Company Details
Table 83. Merck Business Overview
Table 84. Merck Product
Table 85. Merck Revenue in Ischemic Stroke Drugs Business (2015-2020) (Million US$)
Table 86. Merck Recent Development
Table 87. Boehringer Ingelheim Company Details
Table 88. Boehringer Ingelheim Business Overview
Table 89. Boehringer Ingelheim Product
Table 90. Boehringer Ingelheim Revenue in Ischemic Stroke Drugs Business (2015-2020) (Million US$)
Table 91. Boehringer Ingelheim Recent Development
Table 92. Sanofi Company Details
Table 93. Sanofi Business Overview
Table 94. Sanofi Product
Table 95. Sanofi Revenue in Ischemic Stroke Drugs Business (2015-2020) (Million US$)
Table 96. Sanofi Recent Development
Table 97. Johnson & Johnson Company Details
Table 98. Johnson & Johnson Business Overview
Table 99. Johnson & Johnson Product
Table 100. Johnson & Johnson Revenue in Ischemic Stroke Drugs Business (2015-2020) (Million US$)
Table 101. Johnson & Johnson Recent Development
Table 102. Bayer Company Details
Table 103. Bayer Business Overview
Table 104. Bayer Product
Table 105. Bayer Revenue in Ischemic Stroke Drugs Business (2015-2020) (Million US$)
Table 106. Bayer Recent Development
Table 107. Biogen Company Details
Table 108. Biogen Business Overview
Table 109. Biogen Product
Table 110. Biogen Revenue in Ischemic Stroke Drugs Business (2015-2020) (Million US$)
Table 111. Biogen Recent Development
Table 112. Abbott Laboratories Business Overview
Table 113. Abbott Laboratories Product
Table 114. Abbott Laboratories Company Details
Table 115. Abbott Laboratories Revenue in Ischemic Stroke Drugs Business (2015-2020) (Million US$)
Table 116. Abbott Laboratories Recent Development
Table 117. Genentech Company Details
Table 118. Genentech Business Overview
Table 119. Genentech Product
Table 120. Genentech Revenue in Ischemic Stroke Drugs Business (2015-2020) (Million US$)
Table 121. Genentech Recent Development
Table 122. Daiichi Sankyo Company Details
Table 123. Daiichi Sankyo Business Overview
Table 124. Daiichi Sankyo Product
Table 125. Daiichi Sankyo Revenue in Ischemic Stroke Drugs Business (2015-2020) (Million US$)
Table 126. Daiichi Sankyo Recent Development
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Ischemic Stroke Drugs Market Share by Type: 2020 VS 2026
Figure 2. Tissue Plasminogen Activator Features
Figure 3. Anticoagulant Features
Figure 4. Antiplatelet Features
Figure 5. Antihypertensive Features
Figure 6. Others Features
Figure 7. Global Ischemic Stroke Drugs Market Share by Application: 2020 VS 2026
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Ambulatory Surgical Centers Case Studies
Figure 11. Others Case Studies
Figure 12. Ischemic Stroke Drugs Report Years Considered
Figure 13. Global Ischemic Stroke Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Ischemic Stroke Drugs Market Share by Regions: 2020 VS 2026
Figure 15. Global Ischemic Stroke Drugs Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Ischemic Stroke Drugs Market Share by Players in 2019
Figure 18. Global Top Ischemic Stroke Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ischemic Stroke Drugs as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Ischemic Stroke Drugs Revenue in 2019
Figure 20. North America Ischemic Stroke Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Ischemic Stroke Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Ischemic Stroke Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Ischemic Stroke Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Ischemic Stroke Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Ischemic Stroke Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Ischemic Stroke Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Bottom-up and Top-down Approaches for This Report
Figure 28. Data Triangulation
Figure 29. Key Executives Interviewed
急性虚血性脳卒中治療薬の世界市場（～2026年） AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics…- 虚血性脳卒中予防治療薬の世界市場（～2026年） Market Analysis and Insights: Global Ischemic Cerebral Stroke Prevention Therapeutics Market The global Ischemic Cerebral Stroke Prevention Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Ischemic Cerebral…
- 虚血性心疾患（IHD）薬の世界市場（～2026年） Ischemic heart disease (IHD), refers to a group of diseases which includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. It is within the group of cardiovascular diseases of which it is the most common type. A common symptom is chest pain or discomfort which may tr…
- 組織プラスミノーゲン活性化因子の世界市場（～2026年） Tissue plasminogen activator (abbreviated tPA or PLAT) is a protein involved in the breakdown of blood clots. It is a serine protease found on endothelial cells, the cells that line the blood vessels. As an enzyme, it catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible f…
- 脳卒中診断・治療の世界市場（～2026年） Stroke refers to the brain attack. Stroke occurs when the supply of blood to the brain is either interrupted or reduced. Increasing number of mergers and acquisitions, rapid product launches, and rise in number of collaborations and partnerships are some of the latest trends that have been observed …